Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes
Authors' conclusion
Dapagliflozin shrinks EAT and LV mass independently of BMI in T2D patients with stage B/C heart failure, supporting EAT as a modifiable target of SGLT2 inhibition. The absence of parallel changes in systemic inflammation suggests primarily local mechanisms.
Study context
- Population
- Adults with T2D and stage B or C HF, Scotland; obesity common (75% BMI ≥30 kg/m²); HFpEF 51%, HFrEF 49%
- Participants
- 122 adults
- Comparison
- Dapagliflozin 10 mg once daily vs placebo for 12 months
- Outcome
- Epicardial adipose tissue (EAT) assessed by cardiac MRI
- Follow-up
- 12 months
Methodological detailsREFORM and DAPA-LVH, phase 2, single-centre, double-blind, placebo-controlled
- REFORM and DAPA-LVH
- Phase 2
- Single-centre
- Double-blind
- Placebo-controlled
Pooled result
As reported in the abstract
Change in EAT
Dapagliflozin
−1.16
± 0.18 · cm²
Placebo
+0.36
± 0.19 · cm²
P < 0.001
Further pooled results
| Outcome | Dapagliflozin | Placebo | P value |
|---|---|---|---|
| Change in BMI · 12 months | −1.17 ± 0.16 kg/m² | −0.18 ± 0.17 kg/m² | P < 0.001 |
| Change in LV mass · 12 months | −3.53 ± 1.77 g | +1.57 ± 1.83 g | P = 0.048 |
Original publication
Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes. Diabetes Obes Metab. Published 6 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →